
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Aurora Cannabis Inc (ACB)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: ACB (1-star) is currently NOT-A-BUY. Pass it for now.
Year Target Price $32.07
Year Target Price $32.07
3 | Strong Buy |
1 | Buy |
2 | Hold |
0 | Under performing |
0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.61% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 235.38M USD | Price to earnings Ratio 18.86 | 1Y Target Price 32.07 |
Price to earnings Ratio 18.86 | 1Y Target Price 32.07 | ||
Volume (30-day avg) - | Beta 3.32 | 52 Weeks Range 3.42 - 7.20 | Updated Date 06/29/2025 |
52 Weeks Range 3.42 - 7.20 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.22 |
Earnings Date
Report Date 2025-06-18 | When - | Estimate 0.13 | Actual -0.43 |
Profitability
Profit Margin 0.66% | Operating Margin (TTM) -32.88% |
Management Effectiveness
Return on Assets (TTM) 0.62% | Return on Equity (TTM) 2.6% |
Valuation
Trailing PE 18.86 | Forward PE 95.24 | Enterprise Value 210538055 | Price to Sales(TTM) 0.69 |
Enterprise Value 210538055 | Price to Sales(TTM) 0.69 | ||
Enterprise Value to Revenue 0.84 | Enterprise Value to EBITDA 5.59 | Shares Outstanding 56246400 | Shares Floating 55998047 |
Shares Outstanding 56246400 | Shares Floating 55998047 | ||
Percent Insiders - | Percent Institutions 19.7 |
Analyst Ratings
Rating 4.17 | Target Price 32.07 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aurora Cannabis Inc

Company Overview
History and Background
Aurora Cannabis Inc. was founded in 2006 in Canada. Initially focused on medical cannabis, it expanded rapidly through acquisitions to become a major player in the global cannabis market. After significant overexpansion and missteps, it has focused on profitability and cost reduction.
Core Business Areas
- Medical Cannabis: Production, distribution, and sale of medical cannabis products to patients. Includes dried flower, oils, and softgels.
- Consumer Cannabis: Production, distribution, and sale of recreational cannabis products to adult consumers. Includes dried flower, edibles, vapes, and concentrates. Although Aurora exited recreational cannabis in Canada, it retains a presence internationally.
- International: Focuses on international expansion including medical cannabis to other countries.
- Plant Propagation: Sale of plant cuttings to other cannabis companies.
Leadership and Structure
Miguel Martin serves as the CEO. The company operates with a functional organizational structure, encompassing production, sales, marketing, research, and finance departments.
Top Products and Market Share
Key Offerings
- Dried Flower: Dried cannabis flower for medical and recreational use. No specific market share data available. Competitors include Canopy Growth, Tilray, and Organigram.
- Cannabis Oils: Cannabis oil extracts for medical use. No specific market share data available. Competitors include Canopy Growth, Tilray, and Organigram.
- Vapes: Vape pens and cartridges containing cannabis oil. No specific market share data available. Competitors include Canopy Growth, Tilray, and Organigram.
- Edibles: Gummies and chocolates. Competitors include Canopy Growth, Tilray, and Organigram.
Market Dynamics
Industry Overview
The cannabis industry is experiencing growth but also faces regulatory uncertainty, price volatility, and strong competition. The industry is in a state of flux, with consolidation and restructuring ongoing.
Positioning
Aurora Cannabis Inc is positioned as a global cannabis company. Its competitive advantages include a strong brand presence (although tarnished) and a portfolio of diverse products. However, it has faced challenges in achieving profitability and managing its debt.
Total Addressable Market (TAM)
The global cannabis market is projected to reach hundreds of billions of dollars in the coming years. Aurora Cannabis Inc is positioned to capture a portion of this market, but faces significant competition and regulatory hurdles. Current estimates place TAM at $149 billion by 2031.
Upturn SWOT Analysis
Strengths
- Established brand recognition
- Global presence
- Diverse product portfolio
- Focus on medical cannabis
- Strong production capabilities
Weaknesses
- History of net losses
- High debt levels
- Past overexpansion
- Dilution of shareholder value
- Inconsistent profitability
Opportunities
- Further international expansion
- Development of innovative cannabis products
- Strategic partnerships
- Continued growth in medical cannabis demand
- Legislative changes leading to broader legalization
Threats
- Intense competition
- Regulatory uncertainty
- Price volatility
- Supply chain disruptions
- Changing consumer preferences
Competitors and Market Share
Key Competitors
- TLRY
- CGC
- CRON
- ACB
Competitive Landscape
Aurora Cannabis Inc faces a highly competitive landscape. Its advantages include a strong brand presence and global reach. Its disadvantages include its high debt levels and inconsistent profitability.
Major Acquisitions
MedReleaf
- Year: 2018
- Acquisition Price (USD millions): 2500
- Strategic Rationale: Expanded production capacity and product portfolio. Proved value destructive.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was rapid initially, driven by acquisitions. However, growth has slowed significantly in recent years, and the company has focused on cost cutting and achieving profitability.
Future Projections: Future growth projections are dependent on the company's ability to execute its strategic plan, reduce debt, and achieve profitability. Analyst estimates vary widely depending on assumptions about the cannabis market and regulatory environment.
Recent Initiatives: Recent strategic initiatives include cost reduction programs, a focus on medical cannabis, and international expansion.
Summary
Aurora Cannabis Inc. is striving for profitability in a competitive market. It has made progress in reducing costs and focusing on high-margin products. However, it needs to continue improving its financial performance and managing its debt to ensure long-term success. Investors should monitor the company's progress in achieving profitability and its ability to navigate the evolving cannabis market and associated regulations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be outdated and subject to change. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aurora Cannabis Inc
Exchange NASDAQ | Headquaters Edmonton, AB, Canada | ||
IPO Launch date 2014-07-11 | CEO & Executive Chairman Mr. Miguel Martin | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website https://www.auroramj.com |
Full time employees - | Website https://www.auroramj.com |
Aurora Cannabis Inc., together with its subsidiaries, engages in production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation. The company offers medical and consumer cannabis products; sale of medical and consumer use cannabis products; and the propagation of vegetables and floral plants. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.